Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Negative trial results of custirsen for metastatic prostate cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 1039
Rating:

Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France

Dr Fizazi presents, at a press conference at ESMO 2016, the results of the AFFINITY trial of custirsen, a clusterin upstream inhibitor which had previous indications of improved clinical outcomes for castration resistant prostate cancer.

He describes the results from the AFFINITY trial as failing to reach significant difference in overall survival, and considers future paths for clusterin-targeted cancer therapy.

Dr Fizazi spoke with ecancer to discuss these results, and news coverage of this story is available here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation